Cowen Starts Voyager Therapeutics (VYGR) at Outperform

Cowen initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Outperform rating.

Analyst Phil Nadeau commented, "Voyager’s lead program is VY-AADC01 for the treatment of advanced Parkinson’s disease which is on track to produce proof-of-concept data in 2016. We estimate that VY-AADC01 could address a $1B+ worldwide opportunity and our DCF analysis suggest that Voyager is undervalued for VY-AADC01 alone, with no contribution from other pipeline programs. We are initiating coverage with an Outperform rating."

For an analyst ratings summary and ratings history on Voyager Therapeutics click here. For more ratings news on Voyager Therapeutics click here.

Shares of Voyager Therapeutics closed at $29.25 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)